Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD
2024-511089-36-00Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis and Crohn's disease comparing TEV-48574 dose-ranging with Placebo (2 arms). Primary endpoints: Clinical remission in ulcerative colitis and Endoscopic response in Crohn's disease. Started May 2024; status: completed.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2024-511089-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511089-36-00.